Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Next Previous
Trial Profile

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baloxavir-marboxil (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOCKSTONE
  • Sponsors Shionogi

    • Most Recent Events

    • 04 Jul 2023 According to a Shionogi media release, the company has filed for a supplemental new drug application (sNDA) of Xofluza (baloxavir marboxil) in Taiwan for treatment and post-exposure prophylaxis for influenza virus infection for pediatrics aged 5 to under 12 years.
    • 11 Aug 2022 According to a Genentech media release, Dr. Pedro Piedra is the investigator of the study
    • 11 Jan 2021 According to a Roche media release, the European Commission (EC) has approved Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top